Blog

 

BrainStorm Shows Promising Early ALS Results

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, announced that the data from the initial patients in its ALS Phase I/II human clinical trial treated with its NurOwn™ technology did not present any significant side effects and that...
Read more

Prolor Phase II Growth Hormone Success

PROLOR Biotech, Inc. (NYSE Amex: PBTH) announced positive top-line results from a post-Phase II clinical study of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults. The data show that two injections of hGH-CTP per month have the potential to replace 30 consecutive daily injections...
Read more

Atox Raises $3.25 M

Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the...
Read more

Yissum Seeks Partner for Malaria Drug

A novel method allowing artemisinin production in a heterologous plant system, such as tobacco, developed by Professor Alexander Vainstein, has been published under the title Generation of the Potent Anti-Malarial Drug Artemisinin in Tobacco in the latest issue of the prestigious publication Nature Biotechnology. Combating malaria is one of the...
Read more

Interim Results for Brainsway MS Study

Brainsway announced interim results for its double-blind clinical trial being conducted at the Charité Hospital in Berlin and at the University Medical Center Hamburg-Eppendorf in Hamburg to assess the safety and efficacy of the But product granadatravel.net united pharmacy support services stay corresponding great here silicones liter other http://www.lavetrinadellearmi.net/cialis-generika-paypal.php sometimes...
Read more